Praxis Precision Medicines, Inc. (PRAX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$536.8M
Cash & Equivalents
$86.2M
Quarterly Burn Rate
19 mo
Est. Cash Runway
$9,956M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (8)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06252649 | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Particip... | PHASE3 | Recruiting | 450 |
| NCT07076199 | A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insuli... | PHASE3 | Recruiting | 877 |
| NCT06091865 | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined ... | PHASE3 | Recruiting | 904 |
| NCT06091254 | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Di... | PHASE3 | Recruiting | 822 |
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophage... | PHASE3 | Recruiting | 550 |
| NCT02629159 | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S... | PHASE3 | Active Not Recruiting | 1,629 |
| NCT04232553 | A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease | PHASE3 | Active Not Recruiting | 996 |
| NCT04589845 | Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | PHASE2 | Active Not Recruiting | 920 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.